Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents

BACKGROUND: Neisseria meningitidis serogroup B (MnB) is a leading cause of invasive meningococcal disease in adolescents and young adults. A recombinant factor H binding protein (fHBP) vaccine (Trumenba(®); bivalent rLP2086) was recently approved in the United States in individuals aged 10–25 years....

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Pediatric Infect Dis Soc
Main Authors: Vesikari, Timo, Østergaard, Lars, Diez-Domingo, Javier, Wysocki, Jacek, Flodmark, Carl-Erik, Beeslaar, Johannes, Eiden, Joseph, Jiang, Qin, Jansen, Kathrin U., Jones, Thomas R., Harris, Shannon L., O'Neill, Robert E., York, Laura J., Crowther, Graham, Perez, John L.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2016
Assuntos:
Original Articles and Commentaries
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5407127/
https://ncbi.nlm.nih.gov/pubmed/26407272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jpids/piv039
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares